Key result
Pharmacist-led medication review with follow-up significantly improved clinical goal achievement for hypertension (OR 4.37; 95% CI 2.54-7.51; P=0.001) and other CVD risk factors compared to usual care.
Why the study?
Pharmacist-led medication review with follow-up improves cardiovascular risk factor control in Europe and North America, but differing healthcare systems in Chile preclude generalizability.
Does pharmacist-led medication review with follow-up improve cardiovascular disease risk factor control and medication adherence in older patients with polypharmacy?
RCT (n=324)
cluster-randomized
Yes
Does pharmacist-led medication review with follow-up improve cardiovascular disease risk factor control and medication adherence in older patients with polypharmacy?
Answers are grounded in this paper and cite their sources.
Pharmacist-led medication review with follow-up significantly improves cardiovascular risk factor control and medication adherence in older patients with polypharmacy in primary care.
AIMS: Cardiovascular diseases (CVD) are the primary cause of death in Chile. Pharmacist-led medication review with follow-up (MRF) has improved CVD risk factors control in Europe and North America. However, their healthcare systems differ from Chile's, precluding generalizability. This trial aimed to determine the effect of MRF on CVD risk factor control among older patients with polypharmacy attending public primary care centres in Chile. METHODS: A cluster-randomized controlled trial was conducted in 24 centres. Patients older than 65 years with moderate-to-high CVD risk, five or more medications, hypertension, type 2 diabetes or dyslipidaemia, received MRF in addition to usual care or usual care alone for 12 months. Primary outcome measures were clinical goal achievement for hypertension, type 2 diabetes and dyslipidaemia, as well as medication adherence, medication number and CVD risk score. Adjusted generalized estimating equations were used, with odds ratios (ORs) for binary measures and mean differences for continuous measures. RESULTS: In total, 324 patients from 12 centres (174 MRF group, 150 usual care group, six centres each) received four pharmacist visits. Significant improvements were found for goal achievement in hypertension (OR 4.37, 95% confidence interval [CI] 2.54 to 7.51, P = .001), LDL cholesterol (OR 3.67, 95% CI 2.13 to 6.33, P = .001), type 2 diabetes (OR 6.97, 95% CI 3.69 to 13.2, P = .001), medication adherence (OR 6.60, 95% CI 1.36 to 31.9, P = .022), medications number (-0.86, 95% CI -1.14 to -0.58, P < .001) and CVD risk score (-2.27, 95% CI -2.84 to -1.69, P < .001). CONCLUSION: Pharmacist-led medication review with follow-up improved cardiovascular disease risk factor control and medication adherence. This study supports pharmacists' inclusion in primary care teams.
No takes yet. Share an insight, caveat, or question.
Martínez‐Mardones et al. (2023) conducted an RCT in Cardiovascular disease risk factors (n=324). Pharmacist-led medication review with follow-up (MRF) vs. usual care was evaluated on clinical goal achievement for hypertension (OR 4.37, 95% CI 2.54-7.51, p=0.001). Pharmacist-led medication review with follow-up significantly improved clinical goal achievement for hypertension (OR 4.37; 95% CI 2.54-7.51; P=0.001) and other CVD risk factors compared to usual care.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: